NICE will continue to offer joint advice with the Medicines and Healthcare products Regulatory Agenc...
Read moreThe law provides a legal framework for the automatic substitution of biosimilars at the level of the...
Read moreNICE was the first EU HTA body to provide their assessment of Kymriah for ALL, publishing their opin...
Read moreSpeaking at the international pharma conference, NICE’s chief executive Sir Andrew Dillon struck a...
Read moreA new game changing treatment for people with multiple myeloma will now be available on the NHS in E...
Read moreConclusion: Blincyto has significant clinical benefits, but that further evidence on cost-effective...
Read moreNHS England continues to develop its pricing and reimbursement expertise by appointing Blake Dark, a...
Read moreIf the French government is able to deliver, pharmaceutical companies can look forward to potentiall...
Read moreDetermine the potential price and reimbursement status of a prospective business development asset.
Read moreUnderstanding payer value and evidence requirements to secure pricing and reimbursement for an oncol...
Read more